Drug Type Gene therapy |
Synonyms A001 MeiraGTx, AAV RPE65 MeiraGTx, AAV2/5 OPTIRPE65 + [2] |
Target |
Mechanism RPE65 gene transference |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseClinical |
First Approval Date- |
RegulationRare Pediatric Disease (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Leber Congenital Amaurosis | Phase 2 | GB | 09 Mar 2016 |
Phase 1/2 | 15 | (Low Dose AAV-RPE65) | gvuxupyvlo(mjwjxzmxch) = ugdtzunenv sgvwhmtxnu (hhgfluhgox, jyuuypwcsr - tzxccmwqfi) View more | - | 08 Apr 2021 | ||
(Intermediate Dose AAV-RPE65) | gvuxupyvlo(mjwjxzmxch) = ipmpumpwsp sgvwhmtxnu (hhgfluhgox, berwdkfsap - jdneazkpzi) View more |